Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

onse to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

For more information about docetaxel (taxotere(R)) please visit http://www.taxotere.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities comm
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS and NEW YORK ... (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care ... public offering of 3,500,000 shares of common stock, and ... of common stock, at an offering price of $4.00 ... a per share exercise price of $5.00, are exercisable ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... , , , , , , , , ... -- NeoStem, Inc.,(NYSE Amex: NBS ) ("NeoStem" or the "Company"), ... , announced,today that it priced a public offering of 5,000,000 shares ... from the offering, after underwriting,discounts and commissions and expenses, will be ...
... , , , , ... 3SBio Inc. ( SSRX),("3SBio" or "the Company"), a leading China ... its unaudited financial results,for the fourth quarter and full year ended ... Financial Highlights:, -- Total net revenues in 2009 increased ...
... growth call for sweeping changes in how the world produces ... including an expert in plant genetics at the University of ... science and technology adviser to Secretary of State Hillary Clinton, ... popular biases against the use of agricultural biotechnology," as well ...
Cached Biology Technology:NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 2NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 3NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 43SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 163SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 173SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 183SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 193SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 203SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 213SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 223SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 233SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 243SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 253SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 26Dramatic changes in agriculture needed as world warms and grows, researchers say 2
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... available in German . Leaf beetles fascinate ... coloring. Their larvae, however, are dangerous plant pests. Larvae of ... tree species: willow and birch. To fend off predator attacks, ... whose precursors they ingest with their leafy food. Scientists ...
... animals, their genes, and their ecosystems (such as rainforests ... than the last mass extinction 65 million years ago. ... that exist today are estimated to be extinct by ... integral part of this extensive network of life. We ...
... This release is available in French . ... today on the grounds of the Botanical Garden. The new ... the Botanical Garden and the Montral Insectarium, two Espace pour ... facilities for research into biodiversity, its preservation and its promotion. ...
Cached Biology News:Host change alters toxic cocktail 2Host change alters toxic cocktail 3Earth's biodiversity: What do we know and where are we headed? 2Earth's biodiversity: What do we know and where are we headed? 3The University of Montreal Biodiversity Centre opens 2The University of Montreal Biodiversity Centre opens 3
Mouse monoclonal antibody to PPP2R2C - protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform...
Mouse monoclonal antibody to PARK2 - Parkinson disease (autosomal recessive, juvenile) 2, parkin...
... used to quantitate double-stranded DNA (dsDNA) in solution, ... With this kit, DNA is stained with Hoechst ... VersaFluor or other fluorometer. The kit quantitates dsDNA ... to 5 micrograms per ml and contains Hoechst ...
... combines enterprise-scale sequence analysis software with the DeCypher ... With DeCypher, you can perform searches like these ... NCBI NT database in under 6 days ... DNA Use HMM analysis to compare ...
Biology Products: